Published: 27 May 2022
Author(s): Waqas Ullah, Muhammad Khawar Sana, Hamza Usman Mustafa, Harigopal Sandhyavenu, Alexander Hajduczok, Tanveer Mir, David L. Fischman, Mahek Shah, Yevgeniy Brailovsky, Indranee N. Rajapreyar
Issue: October 2022
Section: Original article

Acute decompensated heart failure, a constellation of dyspnea, edema, and fatigue due to volume overload, accounts for the high healthcare costs, projected to increase from $21 billion in 2012 to $70 billion in 2030 [1–4]. Therapies such as diuretics and ultrafiltration (UF) have been explored to target volume overload in patients with HF with reduced ejection fraction (HFrEF). Decongestion with diuretics has proven benefits in terms of decreasing symptoms and HF-related hospitalizations [5]. However, continuous or repeated diuretic use has been linked with decremental responses and increased resistance.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.